X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare STRIDES PHARMA SCIENCE with J.B.Chemicals - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

STRIDES PHARMA SCIENCE vs J.B.CHEMICALS - Comparison Results

STRIDES PHARMA SCIENCE    Change

Strides Arcolab is an Indian pharmaceutical company headquartered at Bangalore. The company is primarily involved in two businesses notably the pharma business and the specialized sterile products business branded as Agila. This segment focuses large... More

J.B.CHEMICALS 
   Change

JB Chemicals and Pharmaceuticals Limited (JBCPL), the flagship of the Unique Group, is one of the India's leading transnational pharmaceutical company. The company has 11 manufacturing facilities at four locations in India (Belapur, Ankleshwar, Panol... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    STRIDES PHARMA SCIENCE J.B.CHEMICALS STRIDES PHARMA SCIENCE/
J.B.CHEMICALS
 
P/E (TTM) x 50.9 17.7 287.2% View Chart
P/BV x 1.1 2.4 46.2% View Chart
Dividend Yield % 0.4 0.2 271.4%  

Financials

 STRIDES PHARMA SCIENCE   J.B.CHEMICALS
EQUITY SHARE DATA
    STRIDES PHARMA SCIENCE
Mar-18
J.B.CHEMICALS
Mar-16
STRIDES PHARMA SCIENCE/
J.B.CHEMICALS
5-Yr Chart
Click to enlarge
High Rs1,147318 360.6%   
Low Rs642200 321.8%   
Sales per share (Unadj.) Rs317.2148.0 214.4%  
Earnings per share (Unadj.) Rs7.819.1 41.1%  
Cash flow per share (Unadj.) Rs25.123.9 104.6%  
Dividends per share (Unadj.) Rs2.000.50 400.0%  
Dividend yield (eoy) %0.20.2 115.7%  
Book value per share (Unadj.) Rs274.3128.9 212.7%  
Shares outstanding (eoy) m89.5084.82 105.5%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x2.81.7 161.2%   
Avg P/E ratio x114.013.6 840.8%  
P/CF ratio (eoy) x35.710.8 330.3%  
Price / Book Value ratio x3.32.0 162.5%  
Dividend payout %25.52.6 973.1%   
Avg Mkt Cap Rs m80,05821,951 364.7%   
No. of employees `0002.52.7 91.7%   
Total wages/salary Rs m4,3411,841 235.7%   
Avg. sales/employee Rs Th11,325.84,590.9 246.7%   
Avg. wages/employee Rs Th1,731.4673.4 257.1%   
Avg. net profit/employee Rs Th280.1592.1 47.3%   
INCOME DATA
Net Sales Rs m28,39412,551 226.2%  
Other income Rs m941542 173.7%   
Total revenues Rs m29,33413,093 224.0%   
Gross profit Rs m3,9652,055 193.0%  
Depreciation Rs m1,540412 373.5%   
Interest Rs m1,96296 2,050.6%   
Profit before tax Rs m1,4032,088 67.2%   
Minority Interest Rs m00 0.0%   
Prior Period Items Rs m-1680-   
Extraordinary Inc (Exp) Rs m-4360-   
Tax Rs m97469 20.7%   
Profit after tax Rs m7021,619 43.4%  
Gross profit margin %14.016.4 85.3%  
Effective tax rate %6.922.5 30.9%   
Net profit margin %2.512.9 19.2%  
BALANCE SHEET DATA
Current assets Rs m24,8367,778 319.3%   
Current liabilities Rs m18,9934,358 435.8%   
Net working cap to sales %20.627.2 75.5%  
Current ratio x1.31.8 73.3%  
Inventory Days Days7155 129.8%  
Debtors Days Days11380 141.7%  
Net fixed assets Rs m34,2895,713 600.2%   
Share capital Rs m895170 527.7%   
"Free" reserves Rs m23,65110,547 224.2%   
Net worth Rs m24,54610,937 224.4%   
Long term debt Rs m15,5130-   
Total assets Rs m65,43715,574 420.2%  
Interest coverage x1.722.8 7.5%   
Debt to equity ratio x0.60-  
Sales to assets ratio x0.40.8 53.8%   
Return on assets %4.111.0 37.0%  
Return on equity %2.914.8 19.3%  
Return on capital %6.920.0 34.5%  
Exports to sales %048.7 0.0%   
Imports to sales %07.1 0.0%   
Exports (fob) Rs mNA6,115 0.0%   
Imports (cif) Rs mNA889 0.0%   
Fx inflow Rs m15,6976,169 254.5%   
Fx outflow Rs m7351,285 57.2%   
Net fx Rs m14,9624,884 306.3%   
CASH FLOW
From Operations Rs m1,8711,397 133.9%  
From Investments Rs m5,826-320 -1,818.9%  
From Financial Activity Rs m-10,157-1,196 849.4%  
Net Cashflow Rs m-2,615-102 2,556.1%  

Share Holding

Indian Promoters % 27.7 55.4 50.0%  
Foreign collaborators % 0.0 0.3 -  
Indian inst/Mut Fund % 37.8 3.4 1,115.0%  
FIIs % 8.6 3.9 220.5%  
ADR/GDR % 0.0 0.0 -  
Free float % 25.9 37.0 70.0%  
Shareholders   56,241 30,437 184.8%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare STRIDES PHARMA SCIENCE With:   PFIZER  GSK PHARMA  PANACEA BIOTECH  WYETH LTD  ABBOTT INDIA  

Compare STRIDES PHARMA SCIENCE With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Trades Marginally Higher; Yes Bank & Tata Motors Top Gainers(12:30 pm)

Share markets in India are presently trading on a positive note. Sectoral indices are trading on a positive note with stocks in the realty sector.

Related Views on News

STRIDES PHARMA SCIENCE Announces Quarterly Results (2QFY19); Net Profit Down 72.2% (Quarterly Result Update)

Nov 6, 2018 | Updated on Nov 6, 2018

For the quarter ended September 2018, STRIDES PHARMA SCIENCE has posted a net profit of Rs 54 m (down 72.2% YoY). Sales on the other hand came in at Rs 7 bn (down 26.4% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

STRIDES SHASUN LTD 2017-18 Annual Report Analysis (Annual Result Update)

Oct 1, 2018 | Updated on Oct 1, 2018

Here's an analysis of the annual report of STRIDES SHASUN LTD for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of STRIDES SHASUN LTD. Also includes updates on the valuation of STRIDES SHASUN LTD.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

These Are the Kind of Blue Chips You Should Invest In(The 5 Minute Wrapup)

Nov 9, 2018

All blue chip companies are large caps but all large caps are not blue chips.

Get this Small Cap Logistics Company at a 16% Discount Right Now...(Profit Hunter)

Nov 6, 2018

If you turn the clock back, the current macroeconomic climate is nothing new. The markets have seen them all, and every downcycle has been succeeded by gravity defying gains...more so in the small cap space. This time will be no different.

This Was a Large Cap. But Was It Safe?(Chart Of The Day)

Nov 9, 2018

Investing in large caps is not always safe. Consider the right metrics to judge the safety and quality of large caps.

Why the Realty Sector's Recovery Has Been Delayed(Sector Info)

Nov 15, 2018

NBFC and IL&FS crisis have worsened the realty sector woes. Is there a light at the end of the tunnel for real estate sector?

Does it Make Sense to Invest in Offshore Funds?(Outside View)

Nov 6, 2018

Many investors prefer to invest in offshore funds because of the rupee depreciation and on-going downtrend in the markets, but it is to be invested only when there is no option available to invest in India.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

STRIDES PHARMA SCIENCE SHARE PRICE


Nov 19, 2018 01:33 PM

TRACK STRIDES PHARMA SCIENCE

  • Track your investment in STRIDES PHARMA SCIENCE with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON STRIDES PHARMA SCIENCE

STRIDES PHARMA SCIENCE 5-YR ANALYSIS

COMPARE STRIDES PHARMA SCIENCE WITH

MARKET STATS